AHR and asthma: In passively sensitized medium bronchi, a procedure that reproduces ex vivo the AHR characteristic of asthma, mepolizumab administered at concentrations ≥3 μg/mL significantly (p < 0.05) prevented the His-mediated AHR and at ≥10 μg/mL, the ASM contractility was significantly (p < 0.05) reduced at the same level of that detectable in control tissues [25].